Leukemias and Lymphomas
Leukemia and lymphomas are some of the most common types of cancer in children, affecting one in three children who are diagnosed with pediatric cancer. These diseases are cancers of white blood cells and immune system, hindering the ability of the body to fight off infections. The cancer cells grow too fast and fill up the bone marrow, crowding out the good blood cells. This leaves the body with fewer healthy white blood cells to fight infections.
These trials focus on combinations of medications, therapies and treatment regimens to help the white blood cells and other parts of the immune system prevent infection and to lessen the time or severity of treatment for children of all ages.
Protocol ID: AALL1732
Diseases: Acute lymphoblastic leukemia, B-cell (ALL), Acute lymphoblastic lymphoma (LLy), and Mixed Phenotype Acute Leukemia (MPAL)
Who Can Participate?: New diagnosis, ages 1 to 25
Lead Researcher: Mark A. Ranalli, MD
Protocol ID: AALL1731
Diseases: Acute lymphoblastic leukemia, B-cell (ALL) and Acute lymphoblastic lymphoma (LLy)
Who Can Participate?: New diagnosis, ages 1 - 31
Lead Researcher: Mark A. Ranalli, MD
Protocol ID: AHOD1822
Disease: Hodgkin Lymphoma (HL)
Who Can Participate?: New diagnosis, ages 3 to 25
Lead Researcher: Mark A. Ranalli, MD
Disease: ALL
Who can participate?: Subjects eligible for the study include both males and females, age 1 to < 18 years with newly diagnosed ALL or newly diagnosed lymphomas (T or B cell) and a new CVAD inserted between Day -7 and Day 4 of 3-4 drug systemic induction chemotherapy.
Lead Researcher: Mark A. Ranalli, MD
Protocol ID: T2018-001
Diseases: Acute lymphoblastic leukemia (ALL) and lymphoblastic lymphoma (LLy)
Who Can Participate?: Relapse/Refractory, ages 0 to 21
Lead Researcher: Susan I. Colace, MD
Protocol ID: T2017-002
Disease: ALL
Who can participate?: Patients must be ≤21 years of age at the time of enrollment. Patients must have a diagnosis of relapsed/refractory ALL or LLy with or without extramedullary disease (including CNS2 and CNS3). Patient with mixed phenotype ALL or mature B (Burkitt-like) leukemia are not eligible.
Lead Researcher: Susan I. Colace
Protocol ID: Janssen Daratumumab
Diseases: Acute lymphoblastic leukemia, T-cell (T-ALL) and Acute lymphoblastic lymphoma (LLy)
Who Can Participate?: Replapse/Refractory, ages 1 to 30
Lead Researcher: Susan I. Colace, MD
Protocol ID: AALL1931
Diseases: Acute lymphoblastic leukemia, B-cell (ALL), Acute lymphoblastic leukemia, T-cell (T-ALL), and Acute lymphoblastic lymphoma (LLy)
Who Can Participate?: New diagnosis, ages 0 to 25
Lead Researcher: Mark A. Ranalli, MD
Protocol ID: ADVL1823
Diseases: Acute lymphoblastic leukemia, B-cell (ALL), CNS Tumors, Ewing Sarcoma (EWS), Infantile fibrosarcoma, Osteosarcoma (OS), Rhabdomyosarcoma, and Sarcoma
Who Can Participate?: Replased/Refractory, ages 0 to 30
Lead Researcher: Mark A. Ranalli, MD
Protocol ID: Kymriah MAP
Diseases: Acute lymphoblastic leukemia, B-cell (ALL) and Diffuse Large B-Cell Lymphoma (DLBCL)
Who Can Participate?: Replase/Refractory, ages 0 to 25
Lead Researcher: Dean A. Lee, MD, PhD
Disease: AML
Who can participate?: Children with Down syndrome > 90 days and < 4 years of age at diagnosis of AML or Myelodysplastic Syndrome (MDS).
Lead Researcher: Mark A. Ranalli, MD
Protocol ID: AAML18P1
Disease: Chronic myeloid leukemia (CML)
Who Can Participate?: Ages 0 to 25
Lead Researcher: Mark A. Ranalli, MD
Protocol ID: T2016-002
Disease: Acute Myeloid Leukemia (AML)
Who Can Participate?: Relapse/Refractory, ages 1 to 30
Lead Researcher: Susan I. Colace, MD
Protocol ID: AALL1621
Disease: ALL
Who can participate?: Patient must be ≥ 12 months and < 22 years of age at first diagnosis of APL
Lead Researcher: Mark A. Ranalli, MD
Protocol ID: AALL1631
Disease: ALL
Who can participate?: Ages > 1 year and < 21 years at ALL diagnosis Newly diagnosed de novo ALL (B-ALL or T-ALL) or mixed phenotypic acute leukemia (MPAL meeting 2016 WHO definition) with definitive evidence of BCRABL1 fusion by karyotype, FISH and/or RT-PCR.
Protocol ID: ADVL1521
Disease: ALL
Who can participate?: Patients must be ≥ 1 month and < 22 years of age at the time of study entry. Patients must have had histologic verification of juvenile myelomonocytic leukemia (JMML) at original diagnosis and currently have relapsed or refractory disease.
Protocol ID: Leukemia ONE
Disease: Leukemia, Lymphoma
Who can participate?: Age: infant to 31 years. Undergoing a bone marrow aspiration procedure as part of a diagnostic work up for a potential blood or bone marrow disorder (e.g. leukemia/lymphoma) or as part of ongoing evaluation of response to treatment and peripheral blood draw
Protocol ID: AALL1521
Disease: ALL
Who can participate?: Age > 1 year and ≤ 21 years at time of leukemia diagnosis. Newly diagnosed (de novo) HR Ph-like B-ALL, defined as meeting any one or more of these criteria: Age ≥ 10 years at diagnosis. Has completed a 4-drug regimen Induction therapy.